HCV-ITEM: Human anti-Coronavirus vaccine that induces Specific Tecidual Immunity Multi-Epitope (Q2867174): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: budget (P474): 470,365.24 euro) |
(Changed an Item: modifying budgets in portugal one item from slovenia) |
||||||
| Property / budget | |||||||
500,000.0 Euro
| |||||||
| Property / budget: 500,000.0 Euro / rank | |||||||
Normal rank | |||||||
| Property / EU contribution | |||||||
470,365.0 Euro
| |||||||
| Property / EU contribution: 470,365.0 Euro / rank | |||||||
Normal rank | |||||||
| Property / co-financing rate | |||||||
94.07 percent
| |||||||
| Property / co-financing rate: 94.07 percent / rank | |||||||
Normal rank | |||||||
Revision as of 13:40, 21 October 2021
Project Q2867174 in Portugal
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | HCV-ITEM: Human anti-Coronavirus vaccine that induces Specific Tecidual Immunity Multi-Epitope |
Project Q2867174 in Portugal |
Statements
470,365.0 Euro
0 references
500,000.0 Euro
0 references
94.07 percent
0 references
1 May 2020
0 references
28 February 2021
0 references
IMMUNETHEP, S.A.
0 references
40°21'55.76"N, 8°39'29.95"W
0 references
Face à pandemia de COVID-19 e consequente urgência de soluções terapêuticas, o projeto VHC-ITEM visa a criação e prova de conceito de uma vacina inovadora, de aplicação intranasal, capaz de conferir elevada imunogenicidade face a potenciais mutações do vírus, pela utilização de SARS-CoV-2 atenuado. (Portuguese)
0 references
In view of the COVID-19 pandemic and consequent urgency of therapeutic solutions, the HCV-ITEM project aims to create and test the concept of an innovative vaccine, of intranasal application, capable of conferring high immunogenicity in the face of potential mutations of the virus, through the use of attenuated SARS-CoV-2. (English)
7 July 2021
0 references
Cantanhede
0 references
Identifiers
CENTRO-01-02B7-FEDER-060491
0 references